Newsfeeds - Spark Newswire

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

November 25, 6:25 PM

Gainers XTL Biopharmaceuticals (NASDAQ:XTLB) shares rose 17.74% to $3.65 during Thursday's after-market session. The market value of their outstanding shares is at $19.2 million.

ASMB

1 minute read

Selecta Biosciences Q3 EPS $(0.16) Misses $(0.07) Estimate, Sales $24.43M Beat $12.19M Estimate

By Benzinga Newsdesk

November 9, 9:42 AM

Selecta Biosciences (NASDAQ:SELB) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.07) by 128.57 percent. This is a 77.78 percent decrease over losses of $(0.09) per share

SELB

6 minute read

The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data

By Shanthi Rexaline

November 9, 9:13 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ACHV

21 minute read

Earnings Scheduled For November 9, 2021

By Benzinga Insights

November 9, 5:41 AM

Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings for its third quarter.

AAIC

1 minute read

Selecta Biosciences Posts Encouraging Data For ImmTOR Platform

By Vandana Singh

November 8, 1:39 PM

Selecta Biosciences Inc (NASDAQ:SELB) announced top-line results from the Phase 1 study evaluating the ImmTOR platform to mitigate the formation of…

SELB

1 minute read

Selecta Biosciences, Ginkgo Bioworks Join Forces To Develop Rare Disease Treatments

By Vandana Singh

October 26, 12:15 PM

Selecta Biosciences Inc (NASDAQ:SELB) and Ginkgo Bioworks Holdings Inc (NYSE:DNA) have collaborated to design novel and improved therapeutic potential enzymes for orphan and…

DNA

1 minute read

Selecta In-Licenses Rights To IgG Protease Platform

By Vandana Singh

October 21, 9:50 AM

Selecta Biosciences Inc (NASDAQ:SELB) has announced a strategic licensing agreement to advance a next-generation IgG protease. The partnership leverages Genovis’ immunoglobulin…

SELB

2 minute read

Select Biosciences To Present New Data For ImmTOR Platform At ESGCT 28th Annual Congress On Oct. 19-22

By Benzinga Newsdesk

October 13, 8:14 AM

Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today

SELB